MetaVia (MTVA) AI Stock Analysis

• Market Cap: $14.69M
• Dividend Yield: N/A
• Average Volume (3M): 453.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: N/A
• EPS Growth: -75.88%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 19,588,350
• 10 Day Avg. Volume: 132,880
• 30 Day Avg. Volume: 453,404
• PEG Ratio: 0.01
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.18
• Enterprise Value/Market Cap: -0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.10
• 1Y Price Target: $7.50
• Price Target Upside: 927.40% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 33 Underperform
• Price Target: ―

MetaVia's overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock's high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.

Positive Factors

Financial Outlook

The company expects to have financial runway into 2026, following recent equity financing.

Safety and Tolerability

The safety profile of DA-1726 is differentiated and potentially better than other options, with no treatment-related discontinuations, and GI events being only transient and mild.

Weight Loss Potential

The interim dataset is seen as highly encouraging evidence of DA-1726's weight loss potential and benign safety profile, positioning it as a potential best-in-class weight loss therapy.

Negative Factors

Market Competition

Shares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space from Merck which is also pressuring Viking shares.

Stock Market Reaction

MTVA shares were down 56% on the news, which is viewed as an overreaction on what was only an early-stage study.

MetaVia Business Overview & Revenue Model

Company Description

MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

MetaVia makes money through a diversified revenue model that includes subscription fees for access to its virtual reality platforms and premium content. Additionally, the company generates income through partnerships with other digital service providers and developers who create content for its platforms, often sharing in the revenue generated from these collaborations. Furthermore, MetaVia earns from in-app purchases and virtual goods sales within its ecosystem. Advertising is another key revenue stream, as brands pay for exposure within the virtual environments and experiences offered by MetaVia.

MetaVia Financial Statement Overview

Summary

MetaVia is facing substantial financial challenges, particularly with a lack of revenue and persistent losses. While the company maintains low debt levels, the reliance on equity and negative cash flows suggest operational inefficiencies and financial instability. Strategic shifts are necessary for long-term viability.

Income Statement

MetaVia's income statement shows significant challenges with no revenue generation over the past years. The company consistently reports negative net and gross profits, reflecting high operating losses. The lack of revenue growth and negative profit margins are significant concerns.

Balance Sheet

The balance sheet reveals a moderate financial structure with a debt-to-equity ratio remaining low due to minimal debt. However, the decline in stockholders' equity and high liabilities relative to assets present risks. The equity ratio is decreasing, indicating reliance on liabilities.

Cash Flow

Cash flow analysis indicates consistent negative operating cash flow, highlighting operational challenges. Although free cash flow has deteriorated, the company has managed some financing cash flow. Free cash flow to net income ratio is unfavorable, reflecting cash strain.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00
	EBIT
-28.81M	-15.89M	-19.63M	-15.30M	-29.72M
	EBITDA
-28.79M	-15.88M	-11.76M	-15.24M	-29.67M
	Net Income Common Stockholders
-27.59M	-12.47M	-13.97M	-15.28M	-29.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
16.02M	22.43M	33.36M	16.39M	10.09M
	Total Assets
16.26M	22.78M	33.53M	16.80M	10.97M
	Total Debt
136.00K	203.00K	0.00	71.00K	94.00K
	Net Debt
-15.88M	-22.23M	-33.36M	-16.32M	-9.99M
	Total Liabilities
8.33M	6.10M	11.78M	2.20M	3.77M
	Stockholders Equity
7.93M	16.68M	21.75M	14.60M	7.20M
Cash Flow		Free Cash Flow
-24.72M	-10.85M	-11.71M	-15.14M	-10.77M
	Operating Cash Flow
-24.71M	-10.80M	-11.71M	-15.13M	-10.76M
	Investing Cash Flow
-8.00K	-50.00K	8.00K	-586.00K	69.00K
	Financing Cash Flow
18.30M	-80.00K	28.68M	22.03M	6.86M

MetaVia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.85, and below the 200-day MA of 1.95, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.28 is Neutral, neither overbought nor oversold. The STOCH value of 63.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTVA.

MetaVia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
EVGN	47 Neutral	$12.08M	―	-655.00%	―	-26.38%	40.99%
APLM	42 Neutral	$7.52M	―	-233.67%	―	―	-1786.46%
PTNT	40 Neutral	$4.88M	―		―	-94.07%	52.36%
SLXN	34 Underperform	$7.93M	―	-590.37%	―	―	-73095.97%
MTVA	33 Underperform	$14.69M	―	-339.64%	―	―	-75.88%
RNAZ	27 Underperform	$6.30M	―	-342.99%	―	―	99.64%

MetaVia Corporate Events

MetaVia Reports Positive Phase 1 Trial Results

On April 22, 2025, MetaVia Inc. reported additional positive top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a dual receptor agonist for obesity treatment. The trial demonstrated a dose-dependent response in body weight reduction and significant differences in BMI compared to placebo, without any drug-induced cardiovascular effects. The results suggest DA-1726’s potential as a best-in-class obesity treatment, with a robust safety profile and promising efficacy, particularly in higher doses. MetaVia plans to further explore the maximum tolerated dose and assess its potential in patients who have discontinued other treatments due to tolerability issues.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.

MetaVia’s stock score is heavily impacted by its poor financial performance, with persistent losses and no revenue. Despite positive trial results offering some promise, the stock remains high-risk due to negative valuation metrics and weak technical indicators.

To see Spark’s full report on MTVA stock, click here.

MetaVia Announces Positive Phase 1 Trial Results

On April 15, 2025, MetaVia Inc. announced positive results from the multiple ascending dose Part 2 of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist aimed at treating obesity. The trial demonstrated significant weight loss and safety effects, with a maximum weight reduction of 6.3% and mean reduction of 4.3% at a 32 mg dose. The study showed promising glucose control and waist reduction, with no serious adverse events reported. MetaVia plans to further explore the drug’s potential in a Phase 1 Part 3 study and additional cohorts to determine the maximum tolerated dose.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.

MetaVia’s overall stock score is significantly impacted by its poor financial performance, with persistent losses and a lack of revenue. The technical analysis suggests a weak market position with no upward momentum. Valuation metrics are unfavorable due to negative earnings, making it a high-risk investment. There is a pressing need for strategic operational improvements.

To see Spark’s full report on MTVA stock, click here.